Immunoglobulin heavy chain variable region gene (IGHV) and prediction of time to first treatment (TTFT) in patients with chronic lymphocytic leukemia (CLL): Mutational load or mutational status? Analysis of 1003 cases by F. Morabito et al.
  
Immunoglobulin heavy chain variable region gene (IGHV) and prediction of time to first 
treatment (TTFT) in patients with chronic lymphocytic leukemia (CLL): mutational load or 
mutational status? Analysis of 1003 cases. 
Fortunato Morabito
1
, Tait D Shanafelt
2
, Massimo Gentile
3
, Gianluigi Reda
4
, Francesca Romana 
Mauro
5
, Davide Rossi
6
, Nicola Di Renzo
7
, Stefano Molica
8
, Francesco Angrilli
9
, Annalisa 
Chiarenza
10
, Giovanna Cutrona
11
, Kari G. Chaffee
12
, Sameer A. Parikh
13
, Giovanni Tripepi
14
, 
Graziella D‟Arrigo14, Ernesto Vigna3, Anna Grazia Recchia1, Agostino Cortelezzi4, Gianluca 
Gaidano
15
, Francesco Di Raimondo
10
, Franco Fais
11,16
, Robin Foà
5
, Antonino Neri
4
, Manlio 
Ferrarini
16
 
 
1
Biotechnology Research Unit, Azienda Sanitaria Provinciale di Cosenza, Aprigliano (CS), Italy;
 
2
Department of Medicine, Division of Hematology, Stanford University, CA, United States; 
3
Hematology Unit, Department of Onco-hematology, A.O. of Cosenza, Cosenza, Italy; 
4
Hematology Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy; 
5Hematology, Department of Cellular Biotechnologies and Hematology, „Sapienza‟ University, 
Rome, Italy; 
6
Oncology Institute of Southern Switzerland and Institute of Oncology Research, 
Bellinzona, Switzerland; 
7
Unità di Ematologia, Ospedale Vito Fazzi, Lecce, Italy;
 8
Department of 
Oncology and Haematology, Pugliese-Ciaccio Hospital, Catanzaro, Italy; 
9
Department of 
Hematology, Ospedale Santo Spirito, Pescara, Italy; 
10
Division of Hematology, AOU Policlinico-
OVE, University of Catania, Italy; 
11
UO Molecular Pathology, 
Ospedale Policlinico San Martino IRCCS Genova Italy; 
12
Division of Biomedical Statistics and 
Informatics, Mayo Clinic, Rochester, Minnesota, USA;
 13
Department of Internal Medicine, Division 
of Hematology, Mayo Clinic, Rochester, Minnesota, USA; 
14
Consiglio Nazionale delle Ricerche, 
Istituto di Biomedicina ed Immunologia Molecolare, Reggio Calabria, Italy;
 15
Division of 
Haematology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, 
Italy;
 16
Department of Experimental Medicine, University of Genova, Genoa, Italy 
 
 
Correspondence: Fortunato Morabito, MD, Biotechnology Research Unit, Azienda Sanitaria 
Provinciale di Cosenza, Aprigliano (CS), Italy; e-mail: fortunato_morabito@tiscali.it; Tel: +39-
0984-681329; FAX: +39-0984-681329. 
 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
Thi s article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which 
may lead to differences between this version and the Version of Record. Please cite this 
article as doi: 10.1002/ajh.25206
  
Keywords: Chronic lymphocytic leukemia, IGHV, prognosis, TTFT. 
 
Running Head: Predictive value of the absolute percent deviation of IGHV mutation on TTFT in 
CLL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
  
To the Editor: 
The mutation status of the immunoglobulin heavy chain variable region gene (IGHV) is a 
well-recognized prognostic indicator in patients with chronic lymphocytic leukemia (CLL). The 
occurrence of IGHV somatic hypermutations (SHM) in CLL cells
1
 and the predictive value of its 
presence or absence have been recognized in patients with CLL for roughly 20 years.
2,3 
The cut-off 
value of a 2% deviation from (or ≤98% identity with) the corresponding IGHV germline sequence 
has been used in the initial studies to distinguish „mutated‟ (M-CLL) from „unmutated‟ (UM-CLL) 
cases. Based on this cut-off value, it was determined that unmutated cases had a significantly 
shorter time to first treatment (TTFT) and outcome.
2-4
 This cut-off value was selected based on the 
consideration that differences of IGHV genes from the germline of up to 2% might have been 
related also to allele polymorphisms within the immunoglobulin loci.
5
 These somewhat 
conservative parameters were also suggested by the relative scanty number of sequence data 
available at that time. The frequency of IGHV gene polymorphisms was reported to be 0.0005% by 
a subsequent study suggesting that a cut-off value of 99.99% homology to the germline would be 
sufficient to distinguish truly unmutated from mutated cases.
6
 Some of the subsequent studies 
indicated that a 2% cut-off value was adequate to distinguish two subgroups of patients with a 
different prognostic expectation
7-9
 while others, virtually in equal numbers, proposed different cut-
off values.
10-12
 Despite these discrepancies, the 2% cut-off value is generally adopted in the current 
clinical practice. 
Recently, Jain et al demonstrated in patients treated with the fludarabine, cyclophosphamide 
and rituximab (FCR) regimen that their subsequent course and survival was greatly influenced by 
the amount of mutations present in the IGHV gene segment.
13
 Thus, the higher levels of mutation 
corresponded to a better outcome, pointing to the potential prognostic relevance of the percentage 
of IGHV gene mutation as a continuous rather than a dichotomized variable.
13
 The particular study 
design adopted by Jain et al raises the question of whether their criteria for mutation evaluation 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
  
have a universal value or apply only to patients treated with that particular protocol, as pointed out 
by Gocke and Richardson in a recent commentary.
14
  
We assessed the prognostic significance of the extent of SHM on the TTFT in a large cohort 
of 467 newly diagnosed Binet stage A patients from several Italian institutions who were 
prospectively enrolled in the O-CLL protocol (training cohort, median follow-up 84 months; 
clinicaltrial.gov identifier: 115 NCT00917540). The same analysis was performed on a Mayo Clinic 
validation cohort of 536 cases (median follow-up of 78 months). Further details and data analyses 
are described in the Supplementary Appendix. 
Among the 141 cases classified as UM-CLL in the O-CLL protocol based on the ≤2% 
mutation cut-off point, 94 (67%) did not present any mutation (truly unmutated cases), 31(22%) 
presented a 1% mutation and 16 (11%) presented a 2% mutation (Figure 1A). No significant 
differences were noted in the TTFT of these three groups of patients (Figure 1B). The remaining 
326 cases, classified as mutated in the O-CLL protocol, had a more even distribution among the 
different mutation categories according to criteria similar to those employed by Jain et al. (Figure 
1A). However, no significant differences were observed in terms of risk to be treated in the groups 
of mutated cases stratified according to the extent of SHM (Figure 1C). Similar results were 
observed in the 536 cases of the Mayo Clinic cohort (Figures 1D-F), which provided a further 
validation of the O-CLL data. Thus, a ≥98% homology between the IGHV genes of CLL clones and 
their normal counterpart represents a valid discriminant to distinguish groups with a different 
prognostic likelihood, without a need for a further stratification based upon the extent of IGHV gene 
mutation. 
With the aim of further validating this result, a Cox multivariable analysis was performed 
introducing into the model a minimal number of variables which represented a significant 
discriminant for TTFT in the Cox univariate analysis - i.e., Rai stage (H.R. 2.5, C.I. 2.0-3.2, 
p<0.0001), 2M (H.R. 2.3, C.I. 1.8-2.9, p<0.0001) - together with the extent of IGHV mutation 
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leading to the stratification of CLL cases into different groups.  This analysis was carried out on the 
870 cases in which all the 3 variables were available in both the O-CLL and Mayo Clinic cohorts. 
Notably, in this minimalistic multivariable model, only cases with a IGHV mutational load of 0%, 
>0 to <1% and 1 to ≤2% maintained an independent prognostic impact on TTFT, together with 
2M and Rai stage (Figure 2), while the remaining patient groups, obtained by stratification 
according to the extent of SHM, failed to maintain an independent prognostic relevance. The same 
analysis carried out by a bootstrapping Cox regression model provided similar results 
(Supplementary Table 1). 
In conclusion, this study indicates that a <2% IGHV gene mutation represents a suitable cut-off 
level capable of discriminating cases with a different prognosis. Hence, the classic distinction of 
mutated and unmutated cases may be adequate in the current clinical practice. Furthermore, it 
appears that CLL cases with values below the set cut-off point truly represent the vast majority of 
unmutated cases. Finally, stratification methods based upon the extent of the IGHV mutation do not 
seem [superfluous at least] to add in determining the chance for a given patient to be treated, 
although it remains to be seen whether such stratification may be needed for a more accurate 
prognostication in special clinical situations as those reported by Jain et al.
13
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Figure legends 
Figure 1. Frequency of cases grouped by percentage of IGHV mutations in the O-CLL training 
cohort (A); Kaplan-Meier curves depicted by IGHV mutations equal 0% (a), >0% -1% (b),  >1%-
2% (c), and >2% (d) in the training O-CLL cohort (B); Cox univariate analysis according to 
different percentages of IGHV mutations in the O-CLL training cohort. HR, hazard ratio; CI, 
confidence interval. The bars represent 95% confidence intervals. IGHV>9 was considered as 
reference value (HR=1) (C); Cases grouped by percentage of IGHV mutations in the Mayo Clinic 
validation cohort (D); Kaplan-Meier curves showing IGHV mutations equal 0% (a), >0% and <1% 
(b), >1% to <2% (c), and >2% (d) in the Mayo Clinic validation cohort (E); Cox univariate analysis 
according to different percentages of IGHV mutations in the Mayo Clinic validation cohort. HR, 
hazard ratio; CI, confidence interval. IGHV>9 was considered as reference value. (HR=1) (F). 
Figure 2. Cox multivariate analysis in which Rai stage, 2M and the percentage of IGHV mutations 
combining the O-CLL training and Mayo Clinic validation cohorts, forced in the model. HR, hazard 
ratio; CI, confidence interval. IGHV>9 was considered as reference value. (HR=1).  
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